Leap Therapeutics’ (LPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a report published on Friday morning,Benzinga reports. They currently have a $5.50 price objective on the stock.

Leap Therapeutics Price Performance

Shares of NASDAQ:LPTX traded down $0.15 during trading hours on Friday, hitting $2.74. The company’s stock had a trading volume of 322,359 shares, compared to its average volume of 238,817. Leap Therapeutics has a 52 week low of $1.34 and a 52 week high of $5.00. The company has a market capitalization of $70.14 million, a price-to-earnings ratio of -1.42 and a beta of 0.22. The firm’s fifty day moving average price is $2.94 and its 200 day moving average price is $2.58.

Institutional Trading of Leap Therapeutics

Large investors have recently bought and sold shares of the stock. Simplify Asset Management Inc. boosted its holdings in shares of Leap Therapeutics by 67.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after acquiring an additional 425,626 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after acquiring an additional 457,904 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares during the last quarter. Key Client Fiduciary Advisors LLC boosted its holdings in shares of Leap Therapeutics by 13.0% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after acquiring an additional 37,067 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock worth $750,000 after buying an additional 219,563 shares in the last quarter. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.